Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates

Core Viewpoint - Puma Biotech reported quarterly earnings of $0.43 per share, significantly exceeding the Zacks Consensus Estimate of $0.14 per share, marking an earnings surprise of 207.14% [1][2] Financial Performance - The company achieved revenues of $59.1 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 14.02%, although this represents a decline from year-ago revenues of $72.2 million [2] - Over the last four quarters, Puma Biotech has consistently surpassed consensus EPS estimates [2] Stock Performance - Puma Biotech shares have declined approximately 9.2% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current Zacks Rank for Puma Biotech is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $43.77 million, while the estimate for the current fiscal year is $0.56 on revenues of $231.46 million [7] - The trend of estimate revisions for Puma Biotech is currently mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Puma Biotech belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]